Positive topline results for new anti-VEGF trap therapy


A phase 1/2A trial shows that Opthea s novel anti-VEGF therapy, OPT-302, combined with ranibizumab may be more effective over than ranibizumab alone in inhibiting treating patients with wet AMD.[Read More …] Source: Daily Dose of Eye Care
https://www.lvcenter4sight.com/positive-topline-results-for-new-anti-vegf-trap-therapy/

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s